Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 15 '23 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,667 | Dec 18 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 15 '23 | Sale | 238.50 | 2,000 | 477,000 | 5,667 | Dec 18 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 14 '23 | Option Exercise | 87.92 | 2,000 | 175,840 | 7,667 | Dec 18 04:30 PM | BAKER BROS. ADVISORS LP | Director | Dec 14 '23 | Buy | 228.32 | 20,633 | 4,710,893 | 1,793,403 | Dec 14 06:10 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 14 '23 | Sale | 232.50 | 2,000 | 465,000 | 5,667 | Dec 18 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 13 '23 | Option Exercise | 87.92 | 2,500 | 219,800 | 8,167 | Dec 14 04:30 PM | BAKER BROS. ADVISORS LP | Director | Dec 13 '23 | Buy | 219.39 | 81,159 | 17,805,684 | 1,774,294 | Dec 14 06:10 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 13 '23 | Sale | 225.40 | 2,500 | 563,500 | 5,667 | Dec 14 04:30 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 12 '23 | Option Exercise | 87.92 | 1,300 | 114,296 | 6,967 | Dec 14 04:30 PM | BAKER BROS. ADVISORS LP | Director | Dec 12 '23 | Buy | 218.31 | 34,578 | 7,548,616 | 1,699,129 | Dec 14 06:09 PM | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Dec 12 '23 | Sale | 217.85 | 1,300 | 283,200 | 5,667 | Dec 14 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 05 '23 | Option Exercise | 87.09 | 1,000 | 87,090 | 16,001 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 05 '23 | Sale | 227.33 | 1,000 | 227,330 | 15,001 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 04 '23 | Option Exercise | 81.16 | 1,800 | 146,090 | 16,801 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Dec 04 '23 | Sale | 218.87 | 1,800 | 393,964 | 15,001 | Dec 06 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 30 '23 | Option Exercise | 73.75 | 3,000 | 221,250 | 18,001 | Dec 01 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 30 '23 | Sale | 204.58 | 3,000 | 613,730 | 15,001 | Dec 01 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 29 '23 | Option Exercise | 73.75 | 4,000 | 295,000 | 19,001 | Dec 01 04:30 PM | Lynch Brian Joseph | SVP and General Counsel | Nov 29 '23 | Sale | 199.19 | 4,000 | 796,750 | 15,001 | Dec 01 04:30 PM | BAKER BROS. ADVISORS LP | Director | Nov 21 '23 | Buy | 188.47 | 64,350 | 12,128,340 | 1,667,104 | Nov 21 06:15 PM | BAKER BROS. ADVISORS LP | Director | Nov 20 '23 | Buy | 185.74 | 20,709 | 3,846,575 | 1,607,668 | Nov 21 06:14 PM | BAKER BROS. ADVISORS LP | Director | Nov 17 '23 | Buy | 174.70 | 46,370 | 8,100,704 | 1,588,541 | Nov 21 06:14 PM | BAKER BROS. ADVISORS LP | Director | Nov 15 '23 | Buy | 161.97 | 15,199 | 2,461,721 | 1,545,775 | Nov 15 05:13 PM | BAKER BROS. ADVISORS LP | Director | Nov 14 '23 | Buy | 154.00 | 37,660 | 5,799,653 | 1,500,227 | Nov 15 05:12 PM | BAKER BROS. ADVISORS LP | Director | Nov 14 '23 | Buy | 156.42 | 34,188 | 5,347,837 | 1,531,757 | Nov 15 05:13 PM | BAKER BROS. ADVISORS LP | Director | Nov 13 '23 | Buy | 143.21 | 69,839 | 10,001,368 | 1,465,494 | Nov 15 05:12 PM |
|